A Single-blind Phase 2 Multi-center Randomized Study to

Recruiting

99 years and younger

All

1 Location

Brief description of study

A Single-blind, Phase 2, Multi-center, Randomized Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of the Relaxin Agonist R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients with Hepatorenal Syndrome-Acute Kidney Injury

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Medical Research
Age: - 99 Years
Gender: All

Updated on 12 Apr 2023. Study ID: 853332

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

A Single-blind Phase 2 Multi-center Randomized Study to Assess Safety Tolerability Efficacy and Pharmacokinetics of the Relaxin Agonist R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients with Hepatorenal Syndrome-Acute Kidney Injury

Brief description of study

Eligibility of study

Find a site

What happens next?

Interested in the study